Feb 24, 2021 / 03:40PM GMT
Geoffrey Craig Porges - SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst
Good morning, everybody. I'm Geoff Porges, Director of Therapeutics Research and Senior Biotech Analyst here at SVB Leerink. Welcome to what is now day 3 of our Global Healthcare Conference. I'm delighted to host our next company this morning, which is Regeneron. Regeneron is represented by Justin Holko, who is Vice President of Investor Relations; and Marion McCourt, who is Chief Commercial Officer. Marion and Justin, welcome to GHC. And Justin, I think you have a few remarks.
Justin Holko - Regeneron Pharmaceuticals, Inc. - VP of IR
Thank you, Geoff. Glad to join you today. Before we begin, I would like to remind you that remarks made on today's webcast do include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in the statement. A more complete description of these
Regeneron Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot